Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused in dermatology and oncology, announces positive preliminary results from its consumer trial on Allumera™, demonstrating that the product can improve the appearance of skin. The RevitAll ™ study was designed to...
The Food and Drug Administration (FDA) has informed Photocure that the new drug application (NDA) for Hexvix for detection of non-invasive papillary bladder cancer may be approved pending approval of the PMA for the Karl Storz photodynamic diagnosis system and final agreements between Photocure...